Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has had great success in treating patients with relapsed or refractory B cell malignancies, with CD19-targeting therapies now approved in many countries. However, a subset of patients fails to respond or relapse after CD19 CAR T cell therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Adeel, Komal, Fergusson, Nathan J., Shorr, Risa, Atkins, Harold, Hay, Kevin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819297/
https://www.ncbi.nlm.nih.gov/pubmed/33478595
http://dx.doi.org/10.1186/s13643-021-01588-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819297/
https://www.ncbi.nlm.nih.gov/pubmed/33478595
http://dx.doi.org/10.1186/s13643-021-01588-7

Ejemplares similares